[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"presbyopia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:presbyopia":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,50,78,106,128,148,173,191,218,238,266,288,309,333,354,371,404,429,451,471,499,522,543,569,593],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635938","proof-of-concept-for-a-novel-optical-aperture-contact-lens-in-presbyopia-and-keratoconus-100635938",false,"NCT07559188","Proof-of-Concept for a Novel Optical Aperture Contact Lens in Presbyopia and Keratoconus","NOA","Inclusion Criteria:\n\n* Age ≥ 18y at time of informed consent.\n* Provide written Informed Consent.\n* Being diagnosed in both eyes with:\n* Keratoconus, without having presbyopia (Group A) OR: Emmetropic (+-0.5 D) presbyopia, without having corneal irregularities (Group B)\n* Cornea considered to be clinically stable at the discretion of the investigator (e.g. no recent cross linking performed, no current corneal sutures, no corneal sutures recently removed).\n* Willing to remove current contact lenses (any type) in both eyes for a minimum of 48 hours prior to every study visit.\n* Able to read Dutch.\n\nExclusion Criteria:\n\n* Active ocular infection or inflammation, including infectious keratitis, infectious conjunctivitis or blepharitis with discharge.\n* Medical history (of ocular pathologies) that might lead to incomplete\u002Fincorrect eye surface scan OR wavefront aberrometry, at the discretion of the investigator.\n* Use of fluorescein in the eye, within 12 hours prior to the PentacamAXL Wave scan.\n* Contact lens refitting within one month prior to the screening PentacamAXL Wave scan (or planned refitting throughout the study), as this can significantly impact the corneal or scleral surface.\n* Use of hybrid contact lenses or corneal RGP contact lenses within 3 months prior to (or planned use during) study participation.\n* Having worn contact lenses (any type) within 48 hours prior to performing the screening Pentacam AXL Wave scan at visit 1.\n* Clinically significant acute non-infectious ocular surface abnormality, including active corneal abrasion, recent ocular surface trauma.\n* Severe ocular surface disease that prevents safe lens application, stable wear, or lens removal.\n* Severe corneal hypoesthesia or neurotrophic keratopathy which would impair perception of pain, foreign body sensation or delay symptom reporting.\n* Known hypersensitivity or allergy to the lens material or approved cleaning, disinfecting or filling solutions.\n* Active allergic eye disease, including active papillary or follicular conjunctivitis.\n* Systemic conditions known to impair corneal healing, such as uncontrolled autoimmune disease.\n* Glaucoma.\n* Central opacity and\u002For central corneal scarring and\u002For cataract.\n* History of low corneal endothelial cell count (\\\u003C 1500 cells\u002Fmm2) or endothelial pathologies, at the discretion of the investigator.\n* Aphakic and pseudophakic.\n* Severe meibomian gland dysfunction, at the discretion of the investigator.\n* Known vitreoretinal pathologies, at the discretion of the investigator.\n* Subjects needing eye drops every 2hrs.\n* Pregnant or breastfeeding woman.\n* History of other known ocular pathologies that might influence the measured endpoints of the study, at the discretion of the investigator.","ALL","18 Years",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this clinical study is to evaluate the effectiveness of the NOA lens, a custom-made scleral contact lens developed by Azalea Vision BV, in improving visual quality for individuals with keratoconus and presbyopia.\n\nThis clinical study investigates a new lens design featuring a specific central aperture (opening) intended to enhance image quality by increasing depth of focus and reducing optical aberrations. The NOA lens serves as a functional prototype for future \"smart lens\" technology, specifically the ALMA Smart Lens. The study aims to determine if this specialized lens provides a solution for patients whose visual needs are not fully met by conventional glasses or contact lenses.\n\nThe investigation will compare a standard refractive scleral lens (Type 1) against the aperture-integrated lens (Type 2) to validate the \"pinhole effect\" in improving vision and reducing higher-order aberrations.",[27,28,29,30],"Keratoconus","Presbyopia","Scleral Contact Lenses","Pinhole",[32,33,34,35,36],"keratoconus","presbyopia","scleral contact lenses","pinhole","central aperture","NOT_YET_RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":21},"2026-10-01",{"date":45,"type":21},"2027-03-31",{"name":47,"class":48},"Azalea Vision","INDUSTRY",2,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100630170","contralateral-claims-study-of-clareon-vivity-pro-100630170","NCT07484191","Contralateral Claims Study of Clareon Vivity Pro","Key Inclusion Criteria:\n\n* Cataracts in both eyes.\n* Preoperative corneal astigmatism of less than 1.00 diopter (D) in each eye.\n* Potential postoperative best corrected visual acuity (BCDVA) of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Desires monovision correction.\n* Predicted post-operative residual astigmatism of more than 1D in either eye.\n* Any ocular or systemic co-morbidity that, in the investigator's medical opinion, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject.\n* Other protocol-defined exclusion criteria may apply.","22 Years",{"count":58,"type":21},231,[24],"The purpose of this study is to test new versions of Clareon Vivity Pro intraocular lenses (IOLs) by comparing them to currently marketed IOLs.",[62,28],"Aphakia",[64,65,66],"Cataract","Eye Surgery","Intermediate Vision","RECRUITING","2026-06-11",{"date":70,"type":41},"2026-06-15",{"date":72,"type":41},"2026-04-28",{"date":74,"type":21},"2027-02",{"name":76,"class":48},"Alcon Research",9,{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100643061","refitting-satisfied-infuse-one-day-multifocal-wearers-to-dailies-total1-multifocal-contact-lenses-100643061","NCT07638943","Refitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses","Clinical Outcomes Following Refit From INFUSE One-Day Multifocal to DAILIES TOTAL1 Multifocal in Satisfied Presbyopic Wearers: A Prospective, Open-Label, Single-Arm Study","INFUSETODT1","Inclusion Criteria:\n\nAge ≥40 years at enrollment Current satisfied wearer of Bausch + Lomb INFUSE One-Day Multifocal (kalifilcon A) in both eyes; Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) score \\\u003C12 at baseline Minimum contact lens wear of ≥8 hours\u002Fday, ≥5 days\u002Fweek, for ≥30 days prior to Visit 1 Best-corrected distance visual acuity ≥20\u002F25 (0.18 LogMAR) or better in each eye Manifest refraction within study lens parameters (Sphere: +6.00 D to -10.00 D; Add: Low, Medium, High) Willing to wear DAILIES TOTAL1 Multifocal lenses for ≥8 hours\u002Fday, ≥5 days\u002Fweek and complete all study questionnaires Able to provide written informed consent and comply with investigator instructions\n\nExclusion Criteria:\n\nActive ocular infection, inflammation, or clinically significant ocular surface disease (e.g., severe dry eye, pterygium, keratoconus) Uncontrolled systemic disease or use of systemic medications known to significantly affect the tear film, unless on a stable dose for ≥90 days History of refractive surgery (LASIK, PRK, RK) or intraocular surgery (cataract or IOL implantation) Clinically significant ectropion, entropion, or trichiasis Baseline corneal fluorescein staining score \\>2 in any single zone (NEI\u002FIndustry scale) Current monovision or modified monovision contact lens wear Pregnant or lactating participants Participation in another clinical trial within 30 days prior to enrollment",true,"40 Years",{"count":89,"type":21},30,[24],"The purpose of this study is to determine the comfort and vision of DAILIES TOTAL1 Multifocal contact lenses in a population of satisfied INFUSE One-Day Multifocal contact lens wearers",[93,28],"Contact Lens Comfort and Successful Refitting",[95],"contact lenses","2026-06-09",{"date":68,"type":41},{"date":99,"type":41},"2026-05-20",{"date":101,"type":21},"2027-02-28",{"name":103,"class":104},"Gordon Schanzlin New Vision","OTHER",1,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":105},"100643513","refocus-visability-micro-insert-system-pre-market-clinical-trial-100643513","NCT07637500","Refocus VisAbility™ Micro Insert System Pre-market Clinical Trial","A Prospective, Multicenter Clinical Trial To Evaluate The Safety And The Improvement In Near Visual Acuity In Presbyopic Patients Treated With The VisAbility™ Micro Insert System Through 12 Months","Inclusion Criteria:\n\n1. Subjects must be between ages of 45 to 60 at the time of enrolment.\n2. Subjects must have best corrected distance visual acuity (BCDVA) of 20\u002F20 in each eye.\n3. Subjects must have distance corrected near visual acuity (DCNVA) @ 40 cm of 20\u002F50, 20\u002F63 or 20\u002F80 in each eye.\n4. Subjects must have binocular distance corrected near visual acuity (DCNVA) @ 40 cm of 20\u002F50, 20\u002F63 or 20\u002F80.\n\nExclusion Criteria:\n\n1. Subjects where either pupil has a baseline percent change from scotopic to photopic of less than 30% or an absolute difference of less than 1.00 mm between scotopic and photopic pupil size as measured by the NeurOptics Pupillometer.\n2. Subjects with ocular inflammation, chronic uveitis, or other recurrent anterior or posterior segment inflammatory conditions in either eye; subjects with any ocular or systemic disease(s) posting a significant risk for ocular inflammation, including but not limited to autoimmune disorders (e.g., rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, ulcerative colitis, Crohn's disease, psoriasis, sarcoidosis, Behcet's disease), infections (toxoplasmosis, cat-scratch fe ver, West Nile virus, syphilis, tuberculosis, herpes zoster, herpes simplex, adenovirus), ocular trauma, or gout.\n3. Subjects with scleral thickness of less than 530 microns as measured 3.5 to 4.0 mm posterior to the superior temporal quadrant limbus in either eye.\n4. Subjects with a history of any prior intraocular procedure (e.g., corneal transplant, filtering procedures for glaucoma, vitrectomy, retinal detachment repair, cataract surgery) or any prior refractive procedure (e.g. LASIK, surface excimer, or incisional surgery) in either eye.","45 Years","60 Years",{"count":116,"type":21},33,[24],"The primary study objective is to evaluate the safety and effectiveness of the VisAbility™ Micro Insert System for improvement in binocular distance corrected near visual acuity in presbyopic patients.",[28],"2026-06-04",{"date":96,"type":41},{"date":123,"type":41},"2026-06-02",{"date":125,"type":21},"2027-12",{"name":127,"class":48},"Refocus Group, Inc.",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":49},"100638895","contact-lens-trial-fitting-experience-100638895","NCT07600645","Contact Lens Trial Fitting Experience","Assessment of a Novel Multifocal Contact Lens Trial Fitting Experience","Inclusion Criteria:\n\n1. They are at least 40 years of age.\n2. They understand their rights as a research participant and are willing and able to sign a Statement of Informed Consent.\n3. They habitually wear MyDay sphere or MyDay Energys contact lenses (including sphere lenses for monovision, or sphere lenses for distance vision correction and spectacles for near vision correction).\n4. They have a minimum reading add of +0.75DS (based on their manifest refraction) and no more than +2.50DS.\n5. They have spherical equivalent refractive error between +4.50 to -11.00DS (some restrictions apply based on near add availability)\n6. They have refractive astigmatism of no greater than 0.75DC in each eye.\n7. They are able to achieve distance HCHL visual acuity of +0.10 logMAR or better in each eye with manifest refraction.\n8. They report at least one near-vision difficult symptom consistent with presbyopia as evidenced by a response of 'slight difficult' or worse on ³ 1 item of the Near Activity Visual Questionnaire (NAVQ-P) at screening.\n\nExclusion Criteria:\n\n1. Is participating in any concurrent clinical or research trial.\n2. They have an ocular disorder which would normally contraindicate contact lens wear.\n3. They have a systemic disorder which would normally contraindicate contact lens wear.\n4. They are pseudophakic or aphakic.\n5. They have had corneal refractive surgery.\n6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.\n7. Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable.\n8. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrollment.",{"count":7,"type":21},[24],"This study will assess a trial fitting experience with contact lenses.",[28],"2026-05-18",{"date":141,"type":41},"2026-05-22",{"date":143,"type":21},"2026-05-31",{"date":145,"type":21},"2026-09-01",{"name":147,"class":48},"CooperVision International Limited (CVIL)",{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":105},"100640260","clinical-performance-of-verofilcon-a-toric-contact-lenses-100640260","NCT07586982","Clinical Performance of Verofilcon A Toric Contact Lenses","Clinical Performance of Verofilcon A Toric Contact Lenses in Satisfied Wearers of Senofilcon A Toric Contact Lenses With Blue Light Filtration","Inclusion Criteria:\n\n* Adults, ≥40-year-old, CL wearers with best-corrected 20\u002F20 distance visual acuity or better.\n* Requiring +0.75 ADD or more at standard near distance of 40 cm.\n* Participants will be required to have worn reusable silicone hydrogel toric CLs in the past year and still at a minimum wearing the CLs occasionally without having significant discomfort or dryness.\n* All participants will be required to have a CLDEQ-8 score \\\u003C12.\n* Participants will be required to be able to wear Total 30MFT CLs (presbyopic plus astigmatism both ≥0.75D OD and OS).\n* Astigmatism ranging from 0.75 D to 2.50 D in each eye.\n* Participants will be required to wear the study CLs for ≥13 hours each day with no overnight wear.\n* Willing to wear study CLs for ≥16 hours on the Day 1 (1st full day), Day 14, and Day 29 when responses will be collected via text message.\n* Participants will be willing to wear the CL every day of the week.\n* Participants will be required to provide a glasses prescription that is less than 3 years old.\n* Visual acuity with habitual reusable silicone hydrogel toric CLs is 20\u002F25 or better in each eye.\n\nExclusion Criteria:\n\n* Have worn Total30 MFT in the past\n* Are past rigid CL wearers\n* Are currently wearing monovision CLs\n* Have a history of being diagnosed with dry eye or ocular allergies\n* Have known systemic health conditions that are thought to alter tear film physiology\n* Have a history of viral eye disease\n* Have a history of ocular surgery\n* Have a history of severe ocular trauma\n* Have a history of corneal dystrophies or degenerations\n* Have active ocular infection or inflammation\n* Are currently using isotretinoin-derivatives or ocular medications\n* Are pregnant or breast feeding",{"count":156,"type":21},32,[24],"The goal of this clinical trial is to \\[primary purpose: is to determine if Total30 Multi focal toric conntact lensesare comfortable and the willigness for those who have previously worn reusable toric contact lenses are willing to stay in Total30 MFT after 1 month of wear during the duration of the study. Healthy previous reusable toric contact lens weareres will be refit into total30 MFT contact lenses and will be asked to gauge their comfort while wearing the lenses. Healthy adult participants who are presybyopic between the ages of 18-40 can participant, sex and gender are not disqualifiers unless the participant is pregnant or breast feeding. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]\n\n\\[primary hypothesis or outcome measure 1Proportions of toric CL wearers who have positive visual acuity scores in comfort and vision after one month of wear.\n\n\\[primary hypothesis or outcome measure 2\\]? Contact lens dry eye-8 scores will be less than 12 indicating high levels of comfort after one month of wear.",[160,28],"Contact Lenses",[162,163],"Optometry","Contact lens comfort","2026-05-07",{"date":166,"type":41},"2026-05-14",{"date":168,"type":21},"2026-04",{"date":170,"type":21},"2026-09",{"name":172,"class":104},"Southern College of Optometry",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":190,"locationsCount":105},"100627132","performance-of-two-daily-disposable-multifocal-contact-lenses-100627132","NCT07444658","Performance of Two Daily Disposable Multifocal Contact Lenses","Inclusion Criteria:\n\n1. They are at least 18 years of age.\n2. They understand their rights as a research participant and are willing and able to sign a Statement of Informed Consent.\n3. They habitually use soft contact lenses (multifocal soft contact lenses, sphere lenses for monovision, or sphere lenses for distance vision correction and spectacles for near vision correction,) and have worn lenses at least 3 days a week for at least the past six months.\n4. They have a minimum reading add of +0.75DS (based on their spectacle refraction)\n5. They have spherical equivalent refractive error between +6.00 to -10.00DS at the corneal plane and refractive astigmatism of no greater than -0.75DC in each eye.\n6. They are able to achieve distance HCHL visual acuity of +0.10 logMAR or better in each eye.\n\nExclusion Criteria:\n\n1. They have an ocular disorder which would normally contra-indicate contact lens wear.\n2. They have a systemic disorder which would normally contra-indicate contact lens wear.\n3. They are aphakic.\n4. They have had corneal refractive surgery.\n5. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.",{"count":180,"type":21},35,[24],"This study will compare the performance of two daily disposable multifocal soft contact lenses.",[28],"2026-04-06",{"date":186,"type":41},"2026-04-08",{"date":188,"type":41},"2026-02-24",{"date":143,"type":21},{"name":147,"class":48},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100632315","comparison-of-presbyond-laser-blended-vision-and-conventional-monovision-lasik-in-individuals-with-presbyopia-a-randomized-clinical-study-100632315","NCT07512089","Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A Randomized Clinical Study","Inclusion Criteria:\n\n* Adults aged 40 to 55 years with presbyopia\n* Suitable candidates for LASIK surgery based on clinical evaluation\n* Stable refractive status for at least 1 year\n* Best corrected distance visual acuity within normal range\n* Willing and able to provide written informed consent\n* Willing to comply with study visits and follow-up\n\nExclusion Criteria:\n\n* Previous ocular surgery\n* Corneal disease or abnormal corneal condition that may affect safety\n* Significant ocular disease affecting visual function\n* Severe dry eye or other ocular surface disorders\n* Systemic disease that may affect study participation\n* Inability to tolerate monovision or anisometropia\n* Any condition that the investigator considers unsuitable for the study","55 Years",{"count":199,"type":21},100,[24],"The goal of this clinical trial is to learn if laser blended vision (LBV) works better than traditional monovision LASIK to correct presbyopia in adults aged 40 to 55 years. Presbyopia is an age-related condition that makes it hard to see things up close. The study will also evaluate the safety of both procedures.\n\nThe main questions it aims to answer are:\n\nDoes LBV improve distance, intermediate, and near vision at the same time after surgery? Is LBV as safe as traditional monovision LASIK?\n\nResearchers will compare laser blended vision to traditional monovision LASIK to see if LBV provides better overall vision after surgery.\n\nParticipants will:\n\nBe randomly assigned to receive either laser blended vision or traditional monovision LASIK Have standard eye examinations before surgery Undergo LASIK surgery using the assigned method Return for follow-up visits at 1 week, 1 month, 3 months, and 6 months after surgery Complete vision tests and questionnaires about visual quality and satisfaction",[28,203],"Refractive Error",[28,205,206,207,208,209],"LASIK","Laser Blended Vision","Monovision","Refractive Surgery","Randomized Clinical Trial","2026-03-31",{"date":184,"type":41},{"date":213,"type":21},"2026-04-01",{"date":215,"type":21},"2028-06-30",{"name":217,"class":104},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":105},"100609757","presbyopic-wear-experience-with-multifocal-lenses-compared-to-single-vision-lenses-and-reading-glasses-100609757","NCT07218731","Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasses","Presbyopic Wear Experience With Multifocal Lenses Compared to Single Vision Lenses and Reading Glasse","Inclusion Criteria:\n\n1. At least 40 years of age.\n2. Ability to give informed consent.\n3. Subjects must have corrected distance visual acuity in both eyes equivalent to 20\u002F25 or better at the screening visit.\n4. Require an add power of +0.75 D or greater when tested at 40cm.\n5. Good general health defined by medication use that has not changed within the last 30 days and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the Investigator.\n\nExclusion Criteria:\n\n1. Current or active inflammation or infection as determined by the Investigator.\n2. Current eye disease, infection or inflammation that affects the surface of the eye such as but not limited to moderate or greater blepharitis and ocular allergy.\n3. History of refractive surgery.\n4. Known history of allergy or sensitivity to contact lens solutions and\u002For sodium fluorescein.\n5. Is pregnant or lactating or planning a pregnancy during enrollment of the study.\n6. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable.\n7. Have been diagnosed with dry eye previously\n8. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable.",{"count":89,"type":21},[24],"The purpose of the study is to assess participant experience when wearing multifocal contact lenses compared to spherical contact lenses with reading glasses.",[229,28],"Presbyopia Correction",{"date":231,"type":41},"2026-02-27",{"date":233,"type":41},"2025-12-08",{"date":235,"type":21},"2026-06",{"name":237,"class":104},"Ohio State University",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":86,"sex":17,"minAge":113,"maxAge":246,"enrollmentInfo":247,"targetDuration":248,"studyType":249,"phases":4,"briefSummary":250,"conditions":251,"keywords":252,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":105},"100598936","luminous-efficiency-function-v-of-patients-that-underwent-pseudophakic-presbyopic-corrections-with-edof-iols-100598936","NCT07077967","Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs","Impact of Artificial Lighting on Visual Acuity After Presbyopia Correction With an Extended Depth of Focus Intraocular Lens: Introduction of a Modified Luminous Efficiency Function V(λ)'","V(λ)'_EDOF","Inclusion Criteria:\n\n* age between 45 to 75 years\n\nExclusion Criteria:\n\n* astigmatism \\>1.00 diopters\n* glaucoma\n* former incisional eye surgery\n* corneal or fundus disease\n* diabetes mellitus\n* autoimmune diseases\n* neurological or psychiatric diseases\n* posterior capsule rupture or lens misalignment\n* postoperative uncorrected distance visual acuity \\\u003C 8\u002F10.","75 Years",{"count":199,"type":21},"6 Months","OBSERVATIONAL","Primary objective of this study is to introduce a modified luminous efficiency function that addresses the distinct total eye light transmittance of patients who underwent pseudophakic presbyopic correction with extended-depth of focus (EDOF) intraocular lenses (IOLs) implantations.",[28],[253,254,255,256,257],"pseudophakic presbyopic correction","EDOF intraocular lens","light intensity","eye light transmittance","light efficiency function","2026-02-23",{"date":188,"type":41},{"date":261,"type":41},"2025-10-15",{"date":263,"type":21},"2026-12-15",{"name":265,"class":104},"Democritus University of Thrace",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":249,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":105},"100614851","comfort-and-vision-with-total30-multifocal-lenses-100614851","NCT07284966","Comfort and Vision With TOTAL30 Multifocal Lenses","Evaluation of Wear Comfort and Vision With Total 30 Multifocal Lenses Over 16 Hours of Wear","Inclusion Criteria:\n\nSubjects are eligible for the study if they meet the following criteria:\n\n* Subjects who currently wear soft multi-focal contact lenses and score \\\u003C12 on an entering CLDEQ-8 survey.\n* Subjects who are \\>= 40 years old.\n* Subjects who can and are willing to wear their lenses for 13 hours per day during the study period, and 16 hours per day when questionnaires are being taken.\n* Willing to insert their contact lenses between 6:00 am and 8:00 am on the days when questionnaires will be taken.\n* Vision correctable in soft multi-focal contact lenses to 20\u002F25 (0.10 log MAR) or better in each eye at 6M.\n* Must be able to be successfully fit into the prescription parameters available for Total30 MF contact lenses.\n* Required to have a smartphone and receive push notifications.\n* Willing to attend all study visits.\n* Willing to be diligent about answering the timed surveys in a prompt manner.\n\nExclusion Criteria:\n\nIf any of the following exclusion criteria are applicable, the subject should not be enrolled in the study.\n\n* Ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear.\n* Use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator.\n* Use of isotretinoin-derivatives.\n* Use of lubricating drops.\n* Monocular patients or patients fit with only 1 multifocal lens.\n* Prior refractive surgery.\n* History of herpetic keratitis, ocular surgery, or irregular cornea.\n* Pregnant or lactating.\n* Having participated in a clinical trial in the past 30 days.\n* High-ADD habitual wearers using a different fitting approach than Alcon's multifocal fitting guide (e.g., J\\&J or CooperVision's fitting guide adopting a modified monovision approach).\n* Are past rigid CL wearers.\n* Have a history of being diagnosed with dry eye or ocular allergies.\n* Have history of severe ocular trauma.",{"count":274,"type":21},36,"This study is a single-arm, prospective, observational study conducted at one site to evaluate the comfort and vision of the TOTAL30 Multifocal (T30MF) contact lenses over the course of long wear days. The study will assess the proportion of positive subjective Visual Analog Scale (VAS) assessments of comfort and vision at 10, 12, 14, and 16 hours of wear on Days 1, 7, 14, and 30. Additionally, the study will explore subjective assessments of lens comfort using the CLDEQ-8 survey and measure logMAR visual acuity at both distance and near at Visit 1, Visit 2, and after 1 month of lens wear. Participants will undergo three site visits, with at-home surveys conducted at specified intervals to gather real-time data on comfort and vision.",[277,28,278],"Myopia","Astigmatism","2026-02-06",{"date":281,"type":41},"2026-02-09",{"date":283,"type":41},"2026-02-05",{"date":285,"type":21},"2027-01-21",{"name":287,"class":104},"Scripps Poway Eyecare and Optometry",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":249,"phases":4,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":308},"100520705","ic-8-apthera-iol-new-enrollment-post-approval-study-100520705","NCT06060041","IC-8 Apthera IOL New Enrollment Post Approval Study","Inclusion Criteria:\n\n* 22 years of age or older, any race and any gender;\n* Posterior capsule opacification (PCO) requiring treatment in the IC-8 Apthera IOL eye\n* Able to comprehend and have signed a statement of informed consent;\n* Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits;\n* Clear intraocular media in both eyes;\n* Preoperative corneal astigmatism ≤1.5 D in the IC-8 Apthera IOL eye prior to IC-8 Apthera implantation;\n* Prior IC-8 Apthera IOL implantation in one eye and a monofocal\u002Fmonofocal toric IOL in the other eye in accordance with the directions for use (DFU) for each IOL.\n\nExclusion Criteria:\n\n* Pharmacologically dilated pupil size less than 7.0 mm in the IC-8 Apthera IOL eye;\n* Irregular astigmatism in either eye;\n* History of retinal disease;\n* Active or recurrent anterior segment pathology;\n* Presence of ocular abnormalities;\n* Diagnosis of dry eye in which patients are unable to maintain eye comfort or adequate vision even with dry eye treatment;\n* Previous corneal or intraocular surgery, except cataract surgery;\n* History of ocular trauma or ocular conditions expected to require retinal laser treatment or other surgical intervention;\n* Acute, chronic or uncontrolled systemic disease that would, in the opinion of the investigator, confound the outcomes of the study;\n* Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with hormonal fluctuation that could lead to refractive changes and dry eye;\n* Concurrent participation or participation in any clinical trial up to 30 days prior to the first visit in the study.\n* Subjects who plan to be traveling, relocating or otherwise unavailable to attend any of the visits",{"count":295,"type":21},435,"The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.",[64,28,298],"Posterior Capsule Opacification","2026-01-09",{"date":301,"type":41},"2026-01-12",{"date":303,"type":41},"2023-09-08",{"date":305,"type":21},"2027-09-30",{"name":307,"class":48},"Bausch & Lomb Incorporated",14,{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":321,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":105},"100608980","open-label-multi-center-phase-i-study-of-teclens-quantitative-refractive-crosslinking-in-presbyopia-aged-patients-100608980","NCT07208604","Open Label, Multi-center, Phase I Study of TECLens Quantitative Refractive Crosslinking in Presbyopia-Aged Patients.","Open Label, Multi-center, Phase I Study of TECLens Corneal Crosslinking System for Correction of Refractive Error in Patients of Presbyopia Age.","Inclusion Criteria:\n\n* Adults aged 40-65 years\n* Healthy cornea\n* Refractive error between +4.0 D and -5.0 D\n* Phakic or monofocal pseudophakic (≥6 months post IOL placement)\n* Visual acuity correctable by ±0.25 D\n\nExclusion Criteria:\n\n* Corneal dystrophy, scarring, or prior corneal crosslinking\n* Astigmatism \\>1.0 D\n* Active ocular infection, inflammation, or uncontrolled dry eye\n* Advanced glaucoma or diabetic retinopathy\n* History of delayed corneal healing\n* Pregnancy, breastfeeding, or planning pregnancy during study period\n* Certain medications (e.g., isotretinoin)\n* Recent participation in other investigational drug\u002Fdevice studies (within 30 days)\n* Patients with uncontrolled dry eye or surface disease","65 Years",{"count":7,"type":21},[24],"An 'on-eye' UV delivery system for corneal crosslinking can be used safely and effectively to help free presbyopic patients from the need for reading glasses.",[28],[322,28,277,323],"Corneal crosslinking","Hyperopia","2025-09-28",{"date":326,"type":41},"2025-10-06",{"date":328,"type":21},"2025-09-30",{"date":330,"type":21},"2026-08",{"name":332,"class":48},"TECLens, Inc.",{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":17,"minAge":339,"maxAge":246,"enrollmentInfo":340,"targetDuration":4,"studyType":249,"phases":4,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100585455","north-american-comfilcon-a-clinical-study-100585455","NCT06902584","North American Comfilcon A Clinical Study","Inclusion Criteria:\n\n1. Age 8 to 75 years (inclusive).\n2. Current wearer of the Comfilcon A sphere, toric, multifocal, toric multifocal or Energys contact lens for at least 12 months.\n3. At least occasional overnight wear in the last 12 months.\n\nExclusion Criteria:\n\n1\\. Current participation in a contact lens or contact lens care product clinical trial.","8 Years",{"count":341,"type":21},182,"The main objective of this study is to demonstrate acceptable safety and effectiveness (performance) of comfilcon A Sphere, Toric, Multifocal, Toric Multifocal and Energys lenses, when used in the general population.",[278,28,344],"Ametropia","2025-08-25",{"date":347,"type":41},"2025-08-27",{"date":349,"type":41},"2025-02-05",{"date":351,"type":21},"2025-12",{"name":147,"class":48},4,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":316,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":361,"briefSummary":319,"conditions":362,"keywords":363,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":49},"100603534","quantitative-refractive-crosslinking-in-presbyopia-aged-patients-100603534","NCT07137767","Quantitative Refractive Crosslinking in Presbyopia Aged Patients","Quantitative Refractive Crosslinking in Presbyopia-Aged Patients: An Open Label, Multi-center, Phase I Study of the TECLens Corneal Crosslinking System for Correction of Refractive Error in Patients of Presbyopia Age",{"count":7,"type":21},[24],[28],[322,28,277,323],"2025-08-22",{"date":366,"type":41},"2025-08-29",{"date":368,"type":21},"2025-08-31",{"date":330,"type":21},{"name":332,"class":48},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":86,"sex":17,"minAge":379,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":249,"phases":4,"briefSummary":382,"conditions":383,"keywords":389,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":402,"locationsCount":105},"100603365","my-eyes-my-light-amar-chokh-amar-alo-100603365","NCT07135570","\"My Eyes, My Light\": Amar Chokh, Amar Alo","Stop Blindness in Coastal Bangladesh: Testing the Effectiveness of Community-Based, Artificial Intelligence-Assisted Eye Disease Screening in Coastal Bangladesh","ACA2","Inclusion Criteria:\n\n* Age 35+ years\n* Residing in the Sub-District of Char Fasson in the Bhola District\n\nExclusion Criteria:\n\n* Known eye disease diagnosis","35 Years",{"count":381,"type":21},20000,"Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life. The primary conditions contributing to visual impairment and blindness include cataracts, age-related macular degeneration (AMD), glaucoma, diabetic retinopathy (DR), refractive error, and presbyopia. Early detection of eye disease can provide substantial benefits in prompting treatment to reduce progression and mitigate disability.\n\nCompared with other regions, South Asia has the most cases of visual impairment due to cataracts and uncorrected refractive error. The combination of poverty, poor living and working environments, and limited health care access have long endangered eye health in Bangladesh. Coastal Bangladesh is particularly impacted by eye disease due to economic deprivation and limited healthcare access. The coastal population mostly works in fishing and agriculture, have prolonged sunlight exposure, and inadequate occupational eye protection. This low-lying region, with 35 million people, is especially vulnerable to climate disasters and global warming. High rates of chronic disease, especially diabetes mellitus Type 2 and hypertension, coupled with limited screening and treatment, shape the area's health profile, with the increasing prevalence of eye diseases such as DR, glaucoma, and visual impairment.\n\nTo address the issues of poor health, accessibility, and affordability of eye care, Artificial Intelligence (AI) applications, such as Artificial Intelligence (AI)-assisted fundus imaging, can be applied in eye screening. Medical AI applications have the potential to improve the quality and efficiency of healthcare, reduce healthcare costs, optimize treatment plans, and bolster the development of primary healthcare. They can identify presumptive DR, hypertensive retinopathy (HR), AMD, and glaucoma by analyzing the retina and optic disc of fundus images with moderate accuracy and high efficiency, thus helping address the lack of local eye care professionals.\n\nData Yakka developed a human-AI collaboration that delivers affordable and transformative community-based eye screening to underserved communities in the coastal Bangladesh region of Char Fasson. The \"Amar Chokh Amar Alo\" (My Eyes, My Light) initiative creates and implements comprehensive eye screening that combines AI-assisted eye screening and grassroots partnerships with trusted non-health non-governmental organizations (NGOs). It has three objectives: 1) Enhancing accessibility and affordability of eye screening; 2) Supporting high quality and efficient treatment of those problems detected via screening, 3) Collecting fundus images to refine or train AI algorithms in the future. This project was designed to evaluate the feasibility, performance, equity, and cost of this model of eye screening and its implications for global eye disease.\n\nThe implementation of participant recruitment, data collection, screening, and follow-up was separated into twelve steps. This standardized framework ensured the integration of screening with data collection and follow-up eye care services. Based on risk stratification by diabetes, hypertension, age 50+ years, and\u002For optometrist recommendation, fundus imaging was offered selectively to higher-risk patients.",[384,385,386,64,387,28,277,323,388],"Glaucoma","Diabetic Retinopathy (DR)","Hypertensive Retinopathy","AMD - Age-Related Macular Degeneration","Dacryocystitis",[390,391,392,393,394,395,396],"vision care","eye disease screening","cataracts","glaucoma","age-related macular degeneration","refractive error","Bangladesh","2025-08-19",{"date":364,"type":41},{"date":400,"type":41},"2025-01-05",{"date":235,"type":21},{"name":403,"class":48},"Data Yakka, Inc.",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":86,"sex":17,"minAge":18,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":105},"100296157","clinical-applications-of-advanced-ophthalmic-imaging-100296157","NCT03135327","Clinical Applications of Advanced Ophthalmic Imaging","Observational Phase 1 Group\n\nInclusion Criteria:\n\n1. Self-reported normal healthy subjects;\n2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke;\n3. Who can keep the eye open for imaging.\n\nExclusion Criteria:\n\n1. who can not read and sign the ICF;\n2. who can not receiving ophthalmic imaging;\n3. who cannot tolerate bright light during imaging.\n\nInterventional Phase 2 Group:\n\nInclusion criteria\n\nThe participant will be eligible for entry in the study if s\u002Fhe:\n\n1. Is at least 18 years old and has full legal capacity to volunteer;\n2. Has read and signed the IRB Informed Consent Document;\n3. Is willing and able to follow participant instructions;\n4. Has clear corneas and crystalline lens;\n5. Initial visual acuities were 20\u002F80 or better;\n6. MTHFR C677TT homozygous, or MTHFR C677T\u002FA1298C compound heterozygous with mild to moderate micro-aneurismal vascular retinopathy disease;\n7. Hemoglobin A1c is 10 or less;\n8. Normotensive with or without medications;\n9. Without retinal capillary dropout or macular edema;\n10. Blood homocysteine \\> 9.\n\nExclusion criteria\n\nThe subjects will be ineligible for entry into the study if s\u002Fhe:\n\n1. Has an active ocular disease;\n2. Has had surgery or an eye injury within 6 months.","99 Years",{"count":412,"type":21},5000,[24],"The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.\n\nThere are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.",[416,417,418,28,277,419],"Multiple Sclerosis","Dry Eye Syndromes","Diabetic Retinopathy","Dementia","2025-08-11",{"date":422,"type":41},"2025-08-12",{"date":424,"type":41},"2007-01-01",{"date":426,"type":21},"2029-12-31",{"name":428,"class":104},"University of Miami",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":436,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":49},"100601647","phase-4-quality-of-life-in-presbyopic-patients-who-are-treated-with-qlosi-100601647","NCT07113210","Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Understanding Quality of Life in Presbyopic Patients Who Are Treated With Qlosi","Inclusion Criteria:\n\n* Subjects who are 45-64 years old (inclusive) at the time of screening.\n* Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed.\n* Be able and willing to follow all instructions and attend study visits.\n* Have text messaging capabilities on their phone.\n* Self-reported complaints of near vision blur when fully corrected at distance.\n* Study confirmed near add that is between +0.75 D to +2.00 D OD\u002FOS (inclusive).\n* Spherical distance prescription between +1.00 D to -4.00 D OD\u002FOS (inclusive).\n* Cylinder power less than or equal to -1.00 D OD\u002FOS.\n* Best-corrected visual acuity (BCVA) at distance of 0.00 logMAR (20\u002F20 Snellen equivalent) or better OD\u002FOS.\n\nExclusion Criteria:\n\n* Known hypersensitivity to any ingredient in the study drops.\n* Any active ocular condition that may confound study results (e.g., dry eye, allergy, conjunctivitis, ocular infection).\n* Any use of prescription eye drops 1 week before screening or during the study.\n* Any past use of the study drops.\n* Any contact lens use for the duration of the study.\n* Artificial tears or lubricant eye drops use on the day of or during any study visits.\n* Clinically significant abnormal findings (e.g., central corneal scar) on a slit lamp exam in either eye documented at screening or a known history of a clinically significant slit-lamp finding in either eye that could confound study results.\n* Have had an ocular surgical intervention within 6 months of the screening visit or planned surgical intervention during the study.\n* A female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy.\n* Any visible retinal findings noted upon a dilated fundus examination known to be a risk for use of study treatment (as determined by the investigator).","64 Years",{"count":274,"type":21},[439],"PHASE4","The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments\n\n* Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable).\n* Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.",[28,442,443],"Glasses","Dry Eye","2025-08-07",{"date":422,"type":41},{"date":447,"type":41},"2025-07-18",{"date":449,"type":21},"2025-11-15",{"name":172,"class":104},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":316,"enrollmentInfo":457,"targetDuration":4,"studyType":249,"phases":4,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":470},"100589928","evaluation-of-refractive-outcomes-in-patients-undergoing-presbyond-using-the-mel90-excimer-laser-100589928","NCT06960785","Evaluation of Refractive Outcomes in Patients Undergoing PRESBYOND Using the MEL90 Excimer Laser","Inclusion Criteria:\n\n1. Subjects between 45 and 65 years old\n2. Scheduled to undergo bilateral LASIK treatment with PRESBYOND\n3. Preoperative corrected distance visual acuity of 20\u002F20 Snellen or better in each eye\n4. Normal corneal topography in each eye\n5. Discontinue use of contact lenses at least 1 month for hard contacts and 1 week for soft lenses prior to the preoperative examination\n6. Residual stromal thickness ≥250 microns in each eye\n7. Availability, willingness, to comply with examination follow up visits\n8. Signed informed consent and data protection documents\n9. Patients successfully passed the tolerance test\n\nExclusion Criteria:\n\n1. Mixed astigmatism in any eye\n2. Irregular corneal astigmatism in any eye\n3. Clinically significant ocular surface disease in any eye\n4. History of ocular surgery, ocular pathology, or other significant ocular findings that, in the Investigator's opinion, may increase the patient's risk for corneal refractive surgery or affect potential visual outcomes in each eye\n5. Prior corneal refractive surgery (SMILE, LASIK, LASEK, RK, PRK, etc,) in each eye\n6. Amblyopia, strabismus, nystagmus, forme fruste keratoconus in any eye\n7. Clinically significant pupil abnormalities in any eye\n8. Use of systemic or ocular medications that may affect visual outcomes\n9. Systemic pathology that may affect the results of the study\n10. Pregnancy or being treated for conditions associated with hormonal fluctuation\n11. Participation in another clinical trial in the last 30 days",{"count":458,"type":21},75,"The goal of this clinical trial is to collect information on vision outcomes in people aged 45 to 65 who have difficulty seeing clearly at near distances due to aging (a condition called presbyopia). All participants will receive the same treatment: laser eye surgery with the PRESBYOND method using the MEL 90 excimer laser.\n\nThe main questions this study aims to answer are:\n\n* How well do patients see at distance, intermediate, and near after treatment?\n* How satisfied are patients with their vision after surgery?\n\nParticipants will:\n\n* Attend seven visits over six months (before surgery and after surgery at 1 day, 1 week, 1 month, 3 months, and 6 months)\n* Undergo laser eye surgery with PRESBYOND\n* Complete vision tests and questionnaires about their experience\n\nThere is no comparison group in this study.",[28],"2025-04-29",{"date":463,"type":41},"2025-05-07",{"date":465,"type":21},"2025-05",{"date":467,"type":21},"2026-02",{"name":469,"class":48},"Carl Zeiss Meditec AG",3,{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":246,"enrollmentInfo":478,"targetDuration":4,"studyType":22,"phases":480,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":105},"100588972","phase-2-efficacy-and-safety-of-brimochol-pf-and-carbachol-pf-in-chinese-presbyopia-patients-100588972","NCT06948357","Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients","A Multicenter, Randomized, Double-Blind, Crossover, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of BRIMOCHOL PF, CARBACHOL PF in Chinese Patients With Presbyopia","Inclusion Criteria:\n\n1. At Visit 1 (Screening Period), the age ranges from 45 to 75 years old, regardless of gender\n2. At Visit 1 (Screening Period), the corrected distance visual acuity of either eye is ≥ 0.8 (National Standard Logarithmic Visual Acuity Scale,decimal visual acuity) in the clinical routine manifest refraction (distance vision).\n3. At Visit 1 (Screening Period), the manifest refraction (distance vision under mesopic conditions) results are as follows: For any eye,-4.00D ≤ equivalent spherical lens power ≤ +2.00D, and the negative cylinder lens power is ≥-2.00D;\n4. At least one eye meeting the following at both Visit 1 and Visit 2:\n\n   1. Under mesopic conditions, monocular corrected near visual acuity (MCNVA) ≤65 ETDRS letters (equivalent to decimal visual acuity 0.4) ;\n   2. Under mesopic conditions, monocular corrected near visual acuity with a multiple-pinhole occluder (MCNVA\\_P) improves by ≥15 ETDRS letters compared to monocular corrected near visual acuity without the occluder (MCNVA).\n5. During Visit 1 (Screening Period) and Visit 2, both eyes must meet the following criteria:under mesopic conditions, binocular corrected near visual acuity (BCNVA) is ≤65 ETDRS letters (equivalent to decimal visual acuity 0.4);\n6. Any eye is phakic or implanted with a monofocal intraocular lens (IOL);\n7. Normal iris and pupillary morphology in any eye, with normal light reflex and an interocular pupillary diameter difference ≤1 mm during screening;\n\nExclusion Criteria:\n\n1. Use of corneal or scleral contact lenses within 28 days prior to screening or planned for the duration of the study;\n2. Narrow anterior chamber angle (Van Herick grade ≤2 via slit lamp examination) or previous iridotomy or resection in either eye；\n3. Ocular history in any eye: hyphema, ciliary body detachment, iridodonesis, or ocular trauma；\n4. Any eye with a corneal abnormality that, in the judgment of the investigator, affects visual acuity or intraocular pressure measurements, including moderate to severe dry eye (e.g., significant signs of ocular surface damage (≥5 corneal fluorescein staining spots) on slit lamp microscopy);\n5. Any phakic eye has a history of lens tremor, subluxation, or suspected zonular laxity; or any pseudophakic eye has undergone posterior capsulotomy or uses multifocal or extended depth of focus intraocular lenses.\n6. Any eye with an axial length of ≥26mm;\n7. Either eye has undergone intraocular or corneal surgery (only non-complicated cataract surgery with a monofocal lens placed in the capsular bag more than 6 months after the date of surgery is permitted; complicated cataract surgery is defined as surgery that has resulted in a rupture of the capsule or placement of an IOL outside the capsule (ciliary sulcus, scleral or iris fixation, anterior chamber, etc.));\n8. Either eye has a history of congenital or traumatic cataract, congenital aphakia, or opacities in the refractive media that affect visual acuity in the visual axis area.\n9. History of uveitis, low intraocular pressure (IOP \\\u003C 9 mmHg), glaucoma or hypertension (IOP \\> 21 mmHg) or pseudoexfoliation syndrome in either eye;\n10. Active ocular or periocular infection or inflammation in either eye, or a history of recurrent infection or chronic infection (e.g., herpes virus infection) in either eye;\n11. Either eye has a history of retinal diseases (such as retinal detachment, age-related macular degeneration, diabetic retinopathy, peripheral retinal diseases that increase the risk of the subject as judged by the investigator) or optic nerve abnormalities.\n12. During the screening period, any eye has any ocular disease other than presbyopia that requires treatment with ocular preparations, intravitreal injection or ocular surgery during the study period (except artificial tears, which can be used on the day of ocular examination during the screening period and on non-treatment visits).",{"count":479,"type":21},119,[481],"PHASE2","A multicenter, randomized, double-Blind, crossover, placebo-controlled Phase II clinical Study to evaluate the efficacy and safety of BRIMOCHOL PF and CARBACHOL PF in the treatment of Chinese patients with presbyopia.",[28],[33,485,486,487,488,489,490],"eye drops","ophthalmic solution","Chinese","Brimochol","Carbachol","Brimonidine","2025-04-23",{"date":461,"type":41},{"date":494,"type":41},"2025-03-24",{"date":496,"type":21},"2025-12-30",{"name":498,"class":48},"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":114,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":105},"100581698","the-effects-of-glasses-free-3d-training-on-visual-and-cognitive-function-in-presbyopic-individuals-100581698","NCT06853691","The Effects of Glasses-Free 3D Training on Visual and Cognitive Function in Presbyopic Individuals","Inclusion Criteria:\n\n1. Age 40-60 years old, both sexes;\n2. refractive error -6.0D to 5.0D, astigmatism \\\u003C2.0D, anisometropia \\\u003C4.0D;\n3. binocular corrected visual acuity \\\u003C0.2LogMAR;\n4. stereoscopic threshold ≤100 ';\n5. The subjects could understand the purpose of this study and sign the informed consent.\n\nExclusion Criteria:\n\n1. after lens replacement; People with cataracts, which affect vision, have other eye conditions such that simultaneous vision is not possible;\n2. using any medication known to affect accommodative function or wearing orthokeratology lenses in the past 1 month;\n3. patients with severe systemic disease or severe mental illness;\n4. Other situations where the investigator considers that the subject should not participate in the study for safety reasons or the interests of the patient.",{"count":506,"type":21},60,[24],"This study aims to evaluate the effectiveness of glasses-free 3D visual training in improving visual function, visual comfort, and the application ability of visual functions in individuals with presbyopia. The research will assess changes in brain activity related to visual processing using Electroencephalogram(EEG)and Functional near-infrared spectroscopy(NIRS) before and after the training. By examining the impact of stereoscopic stimulation on the functional connectivity of brain regions, the study seeks to provide new insights into the rehabilitation of presbyopia and its underlying mechanisms. The goal is to offer a non-invasive and scientifically supported approach to improving presbyopia treatment, potentially advancing clinical practices and contributing to brain science and ophthalmology",[28],[28,511,512,513],"visual training","EEG","fNIRS","2025-02-24",{"date":516,"type":41},"2025-03-03",{"date":518,"type":21},"2025-02-27",{"date":520,"type":21},"2026-01-01",{"name":217,"class":104},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":246,"enrollmentInfo":529,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":4},"100512699","evaluation-of-safety-and-effectiveness-of-an-iol-with-a-virtual-aperture-optic-100512699","NCT05955846","Evaluation of Safety and Effectiveness of an IOL With a Virtual Aperture Optic","A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of an Intraocular Lens With a Virtual Aperture Optic","Inclusion Criteria:\n\n1. Adults, Age 40 to 75 years at the time of surgery, diagnosed with bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision and posterior chamber IOL implantation;\n2. Preoperative best-corrected distance visual acuity (BCDVA) worse than 20\u002F30 Snellen;\n3. Clear intraocular media, other than cataract;\n4. Calculated lens power within the available range (available range of +16 D to +24 D);\n5. Preoperative keratometric astigmatism of less than 0.75 D in both operative eyes;\n6. Potential for postoperative BCDVA of 20\u002F25 or better in each eye after cataract removal and IOL implantation;\n7. Able to comprehend and have signed a statement of informed consent;\n8. Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits;\n\nExclusion Criteria:\n\n1. Desire for monovision correction\n2. History of Dry Eye treatments\u002Fdevices (example IPL, Lipiflow, iLux, Tear Care, Bruder Mask, True Tear) or any dry eye medications other than artificial tears (example, Restasis, Xiidra, Cequa, Klarity-C, generic cyclosporine\u002Fcompounded cyclosporine)\n3. Active or recurrent anterior segment pathology (chronic uveitis, iritis, iridocyclitis, rubeosis iridis, Reiter's syndrome, etc.);\n4. Clinically significant corneal abnormalities or defects including corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), irregularity (including irregularity due to dry eye syndrome), inflammation or edema per the Investigator's expert medical opinion. Note: conditions including, but not limited to: keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or keratectasia should be excluded;\n5. Previous corneal or intraocular surgery;\n6. Irregular corneal astigmatism; or regular corneal astigmatism greater than or equal to +\u002F-0.75D;\n7. Inability to achieve stable keratometric readings for contact lens wearers;\n\n   \\*The recommended time for discontinued wear of extended-wear or daily wear soft lenses is one week prior to surgery, one month for gas permeable and six months for PMMA lenses. No evidence of significant corneal warpage from contact lens use should be present on corneal topography and if the subject has been wearing a rigid gas permeable contact lens there should be two stable serial topographies at least 1 month following cessation of contact lens wear\n8. Higher-order Zernike corneal aberrations (3rd -order and above) RMS value greater than 1.0 um for the central 6-mm diameter area;\n9. Pupil dilation in scotopic conditions \\>5mm\n10. Use of systemic or ocular medications that may affect vision or likely to impact pupil dilation or iris structure;\n11. Pharmacologically dilated pupil size less than 6 mm in either eye;\n12. Pupil abnormalities;\n13. History of ocular trauma, prior refractive or other ocular surgery or subjects expected to require retinal laser treatment or other surgical intervention;\n14. Any disease or pathology, other than cataract, that (in the expert opinion of the Investigator) is expected to reduce the potential postoperative BCDVA. Note: Conditions including, but not limited to the following: amblyopia, clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy), diabetic retinopathy, extremely shallow anterior chamber, not due to swollen cataract, microphthalmos, previous retinal detachment, previous corneal transplant, recurrent severe anterior or posterior segment inflammation of unknown etiology, iris; neovascularization, uncontrolled glaucoma, aniridia, or optic nerve atrophy, or diagnosis of pseudoexfoliation;\n15. Neovascularization, uncontrolled glaucoma, aniridia, or optic nerve atrophy;\n16. Subjects who have profound sensitivity to glare at night with oncoming traffic headlights or subjects who are sensitive to fluorescent light flicker;\n17. Subjects who may reasonably be expected to require a SSI at any time during the study (other than YAG capsulotomy);\n18. Subject is pregnant, plans to become pregnant, is lactating or has another condition associated with hormonal fluctuation that could lead to refractive changes and dry eye. Females of childbearing age must have a negative pregnancy test at screening in order to be enrolled into the study.\n19. Concurrent participation or participation in any clinical trial up to 30 days prior to preoperative visit;\n20. Acute, chronic, or uncontrolled systemic or ocular disease or any illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., poorly-controlled diabetes);",{"count":506,"type":21},[24],"Cataracts are cloudy areas in the lens of the eye that can cause changes in vision. Symptoms of cataracts include cloudy or fuzzy vision and sensitivity to glare. Cataract extraction with Intraocular lens (IOL) implantation is the most commonly performed surgical procedure in the world.\n\nPresbyopia affects almost everyone over the age of 50. With age, the natural crystalline lens loses its ability to change shape, or accommodate, to focus on near distances. Thus, individuals with excellent distance vision will still need to wear spectacles for near tasks such as reading, and intermediate tasks such as computer work.",[533,64,28],"Intraocular Lens","2025-01-22",{"date":536,"type":41},"2025-01-27",{"date":538,"type":21},"2025-03-01",{"date":540,"type":21},"2025-09",{"name":542,"class":48},"Z Optics, Inc.",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":551,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":105},"100571026","accommodation-related-visual-training-combined-with-transcranial-electrical-stimulation-versus-visual-training-alone-for-the-treatment-of-accommodation-dysfunction-100571026","NCT06714890","Accommodation-Related Visual Training Combined with Transcranial Electrical Stimulation Versus Visual Training Alone for the Treatment of Accommodation Dysfunction","A Single-center, Prospective, Randomized Controlled Trial Evaluating Accommodation-related Visual Training Combined with Transcranial Electrical Stimulation Versus Accommodation-related Visual Training Alone for the Treatment of Accommodation Dysfunction","Inclusion Criteria:\n\n1. Inclusion criteria for small-angle acute concomitant esotropia: clinical diagnosis of acute aquired concomitant esotropia; strabismus angle ≤ 15PD; age 18 \\\u003C age \\\u003C 40; best corrected visual acuity of both eyes ≥ 1.0.\n2. Inclusion criteria for presbyopia: clinical diagnosis of presbyopia; best corrected visual acuity of both eyes ≥ 1.0.\n\nExclusion Criteria:\n\n1. no history of other eye diseases or eye surgeries\n2. no history of neuropsychiatric diseases for the individual or relatives\n3. no head injuries or surgeries\n4. no history of epilepsy or stroke\n5. no metal implants in the body\n6. no claustrophobia, no metal implants in the body (fracture fixation nails, pacemakers, etc.)\n7. pregnancy",{"count":199,"type":21},[24],"This is a single-center, randomized controlled trial to compare the effectiveness of transcranial electrical stimulation combined with visual training with visual training alone for the treatment of accommodation disorder patients.",[28,554],"Esotropia",[556,28,557,558,559],"Acute Acquired Concomitant Esotropia","Accommodation Disorder","Transcranial Electrical Stimulation","Visual Training","2024-12-03",{"date":562,"type":41},"2024-12-05",{"date":564,"type":21},"2024-12-31",{"date":566,"type":21},"2026-12-31",{"name":568,"class":104},"Eye & ENT Hospital of Fudan University",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":582,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":591,"locationsCount":4},"100569864","quality-of-life-in-presbyopes-using-single-vision-lens-and-progressive-lens-correction-100569864","NCT06699784","Quality of Life in Presbyopes Using Single-vision Lens and Progressive Lens Correction","Quality of Life in Presbyopes Using Single-vision Lens and Progressive Lens Correction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 40-70 years;\n2. A distant correction of ≤2D for hyperopia, or \\>-2 D for myopia, or \\\u003C 2D for astigmatism in both eyes;\n3. Anisometropia of less than 1.50 D;\n4. Distance best-corrected visual acuity (BCVA) of at least 0.5 LogMAR, and near VA \\\u003C N8 (20\u002F50) at 40 cm with habitually worn distance refractive correction, with improvement of near vision by at least one line on a near LogMAR E chart with the use of a plus lens;\n5. Have not undergone any near correction in the past six months;\n6. Able to answer a questionnaire;\n7. Giving written consent to participate in the study.\n\nExclusion Criteria:\n\n1. Ocular abnormalities leading to visual impairment including severe cataract, glaucoma, strabismus, and ocular fundus diseases;\n2. Severe physiological and psychological diseases affecting follow-up;\n3. History of cataract surgery, phakic intraocular lens surgery, corneal surgery, or any intraocular surgery affecting the refractive status of the eye;\n4. Have used pilocarpine in the past six months.","70 Years",{"count":578,"type":21},74,[24],"The goal of this clinical trial is to compare the quality of life (QOL) of presbyopes wearing progressive addition lenses (PALs) with that of those wearing single-vision spectacles (SVSs) for near correction. The main questions it aims to answer is:\n\nWhat is the difference in QOL between presbyopes who use SVSs and those who use PALs ? Eligible participants will be randomly assigned in a 1:1 ratio to either the PALs group or the SVSs group.Participants in the progressive lenses intervention group will receive 1-month progressive lens correction in daily life. And participants in single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.\n\nThe study will compare the QOL scores measured by a 12-item Near Vision-Related Quality of Life questionnaire between the two groups. Additionally, the study will compare the scores measured by the Refractive Status and Vision Profile questionnaire and Visual Analogue Scale questionnaire between the two groups as well as assess the change in the above three questionnaires scores at 1 month following enrollment. And visual acuity of subjects will also be assessed at baseline and at the 1-month follow-up.",[28,229],[583,33,584],"quality of life","near correction","2024-11-19",{"date":587,"type":41},"2024-11-21",{"date":589,"type":21},"2024-12",{"date":351,"type":21},{"name":592,"class":104},"The Hong Kong Polytechnic University",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":22,"phases":603,"briefSummary":604,"conditions":605,"keywords":606,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":49},"100561986","the-vis-opti-k-low-vision-aid-device-provides-vision-improvement-100561986","NCT06597292","The VIS Opti-K Low Vision Aid Device Provides Vision Improvement.","Vision Improvement for Patients With Presbyopia","Opti-K Pres","Inclusion Criteria\n\nSubjects who meet all of the following criteria are candidates for this study:\n\n1. Male or Female\n2. Any race\n3. Patient is at least 40 years old.\n4. Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.\n5. Patient has manifest refraction, spherical equivalent (MRSE) between -0.50 D to 2.50 D, with no more than 1.0 D of refractive cylinder, in eye(s) to be treated.\n6. Patient has uncorrected distance visual acuity (UDVA) of 20\u002F100 or better (i.e., LogMAR ≤ 0.70) in both eyes.\n7. Patient has best corrected distance visual acuity (CDVA) of 20\u002F20 or better (i.e., LogMAR ≤ 0.00) in both eyes.\n8. Patient has uncorrected near visual acuity (UNVA) between 20\u002F50 (LogMAR 0.40) and better than 20\u002F100 (LogMAR \\< 0.70) in eye(s) to be treated.\n9. Patient has best corrected near visual acuity (CNVA) of at least 20\u002F20 (LogMAR ≤ 0.00) in eye(s) to be treated.\n10. Patient requires reading adds of +1.0 to +3.0 D in eye(s) to be treated.\n11. Patient is not a contact lens (CL) wearer.\n12. Patient has normal corneal topography.\n13. Patient is willing and able to comply with all examinations.\n14. Patient must be competent to sign an informed consent form before study entry.\n\nExclusion Criteria\n\nSubjects who meet any of the following criteria are to be excluded from this study:\n\n1. Corneal disease or corneal disorder in either eye.\n2. Any active ocular surface disease of any severity.\n3. Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma.\n4. Previous corneal surgery in the eye to be treated.\n5. Conjunctivochalasis\n6. Nystagnus\n7. Diabetes\n8. Pregnancy\n9. Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.\n\nnclusion Criteria: -\n\nExclusion Criteria:\n\n\\-",{"count":602,"type":21},200,[24],"The VIS Opti-K Low Vision Aid device will be used to provide vision improvement to patients with refractive disorders (hyperopia and presbyopia).",[323,28],[607],"Vision improvement","2024-09-23",{"date":610,"type":41},"2024-09-25",{"date":612,"type":21},"2024-09-16",{"date":614,"type":21},"2026-12-30",{"name":616,"class":48},"VIS, Inc."]